Weight Management Innovation Tour
Information
Participation on site is open to all visitors on a first-come, first-served basis, with a maximum of 25 participants allowed per tour.
In 2022, 2.5 billion people worldwide were overweight and 690 million were obese, representing 43% of the population. If this trend continues, this figure will rise to 50% by 2030 (WHO). Consequently, 42.9% of the global population is trying to lose weight .
The increase of the global market for anti-obesity drugs (Ozempic, Saxenda, Wegovy, Mounjara, etc.), which is expected to reach US$100 billion by 2030 (US$6 billion in 2024), has open opportunity for ingredients either for mimicking drugs or for support consumers under GLP-1 treatment.
This tour will show you the latest innovations for the weight management market.
References:
- Euromonitor Health & Nutrition Survey 2025
- www.goldmansachs.com/insights/articles/anti-obesity-drug-market
Participating Exhibitors:
- Beneo – 6F10
- Sirio Europe GmbH & Co. KG – 3G40
- Reducose® by Phynova – 3B235
- ROELMI HPC – 3K140
- BGG Europe SA – 3C246
- Laboratoire PYC – UWB108
- HTBA (HealthTech Bio Actives) – 5A14
- 3HLABS – 3D154G
- Rousselot SAS – 3C146
- Activ’ Inside – 3C64
- SynBalance Srl – 3K140
